It was a head-turning headline. Here's why the market was buzzing.

Moderna and Merck will present Phase 3 melanoma findings on Saturday for their personalized cancer treatment combined with ...

Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share ...

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Stephen Hoge and Dean Li, at the STAT Summit, spoke of how Merck and Moderna will pair Keytruda with personalized mRNA ...

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the biotechnology company’s vaccines and said it would cancel some contracts and stop ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 9.4% in the afternoon session after positive Phase 3 INTerpath-001 trial results evaluating its personalized cancer vaccine, intismeran ...

Following last month's super rally, a growing number of analysts are now calling for caution.

Moderna MRNA shares suffered a sharp reversal on Friday, falling close to 10% after a strong October rally had pushed the ...

Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares ...

Billionaire biotech mogul Noubar Afeyan has called for urgent regulation of artificial intelligence agents that tech firms ...